Osimertinib works by slowing or stopping the growth of cancer cells and binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors
Aurobindo has one of the most enduring generics ecosystems among peers
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
Adjusted PAT declined 18.8% YoY
The GMP certificate is valid for three years until April 2024.
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr
Subscribe To Our Newsletter & Stay Updated
